Lyndsey Runaas, MD

Assistant Professor

view physician profile

Locations

Froedtert Hospital
Clinical Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Clinical Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Lyndsey Runaas, MD, is an Instructor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in leukemia and allogeneic stem cell transplant at Froedtert Hospital. She graduated with Alpha Omega Alpha Honor Society membership from the University of Wisconsin School of Medicine and Public Health in 2010. She then completed her Internal Medicine residency at the University of Wisconsin in Madison, Wisconsin in 2013, and served as Chief Resident in 2014. Following this, she completed her fellowship in Hematology and Oncology at the University of Michigan in 2017. Her clinical focus is on myeloid malignancies and allogeneic stem cell transplant with research interests in patient-physician communication and patient reported outcomes. Her professional memberships include the American Society of Hematology, American Society of Clinical Oncology and American Society for Blood and Marrow Transplantation.

Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.

(Sorror ML, Saber W, Logan B, Geller N, Bellach A, Kou J, Wood W, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus PH, Hogan WJ, Nadiminti K, Bhatt VR, Olin R, Maakaron J, Sobecks R, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS.) Blood Adv. 2025 Jul 08;9(13):3268-3280 PMID: 40101246 03/18/2025
Accurate prediction of absolute prokaryotic abundance from DNA concentration.

(Wirbel J, Andermann TM, Brooks EF, Evans L, Groth A, Dvorak M, Chakraborty M, Palushaj B, Reynolds GZM, Porter IE, Al Malki M, Rezvani A, Gooptu M, Elmariah H, Runaas L, Fei T, Martens MJ, Bolaños-Meade J, Hamadani M, Holtan S, Jenq R, Peled JU, Horowitz MM, Poston KL, Saber W, Kean LS, Perales MA, Bhatt AS.) Cell Rep Methods. 2025 May 19;5(5):101030 PMID: 40300608 PMCID: PMC12146642 SCOPUS ID: 2-s2.0-105003827989 04/30/2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703.

(Abedin SM, Martens MJ, Bolaños-Meade J, Al Malki MM, Lian Q, Runaas L, Elmariah H, Gooptu M, Larkin K, Shaffer BC, Loren AW, Solh MM, Alousi AM, Jamy O, Perales MA, Rezvani AR, Bhatt AS, El Jurdi N, Yao JM, Applegate K, Kean LS, Efebera YA, Reshef R, Clark WB, Leifer E, Saber W, Horowitz MM, Jones RJ, Holtan SG, Hamadani M.) Blood Adv. 2025 Apr 30 PMID: 40305657 04/30/2025
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

(Abedin SM, Guru Murthy GS, Hamadani M, Michaelis LC, Carlson KS, Runaas L, Gauger K, Desai AG, Chen MM, Li KL, Rotibi M, Syed U, Vusirikala M, Harrington A, Atallah EL.) Leukemia. 2025 Apr;39(4):837-843 PMID: 39955432 SCOPUS ID: 2-s2.0-85218187693 02/16/2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.

(Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ.) J Clin Oncol. 2025 Mar 10;43(8):912-918 PMID: 39752608 PMCID: PMC12124660 SCOPUS ID: 2-s2.0-85214844948 01/03/2025
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.

(Siegel SJ, DeWolf S, Schmalz J, Saber W, Dong J, Martens MJ, Logan B, Albanese A, Iovino L, Chen E, Kaminski J, Neuberg D, Hebert K, Keskula P, Zavistaski J, Steinberg L, Schichter I, Cagnin L, Hernandez V, Warren M, Applegate K, Bar M, Chhabra S, Choi SW, Clark W, Das S, Jenq R, Jones RJ, Levine JE, Murthy H, Rashidi A, Riches M, Sandhu K, Sung AD, Larkin K, Al Malki MM, Gooptu M, Elmariah H, Alousi A, Runaas L, Shaffer B, Rezvani A, El Jurdi N, Loren AW, Scheffey D, Sanders C, Hamadani M, Dudakov J, Bien S, Robins H, Horowitz M, Bolaños-Meade J, Holtan S, Bhatt AS, Perales MA, Kean LS.) medRxiv. 2025 Feb 26 PMID: 40061351 PMCID: PMC11888538 03/10/2025
40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies.

(Corrao K, Umpierrez A, Treml A, Szabo A, Michaelis L, Runaas L, Murthy GSG, Abedin S, Carlson K, Kreuziger LB, Atallah E.) Haematologica. 2025 Jan 30 PMID: 39882645 01/30/2025
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.

(Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E.) Haematologica. 2024 Sep 01;109(9):2864-2872 PMID: 38572562 PMCID: PMC11367232 SCOPUS ID: 2-s2.0-85201433013 04/04/2024
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.

(Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M.) Blood Adv. 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.

(Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M.) Bone Marrow Transplant. 2024 Mar;59(3):373-379 PMID: 38177221 SCOPUS ID: 2-s2.0-85181508004 01/05/2024
Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.

(Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, Atallah EL, Abedin SM.) Leuk Res. 2023 Sep;132:107348 PMID: 37423073 SCOPUS ID: 2-s2.0-85164434355 07/10/2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

(Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators.) N Engl J Med. 2023 Jun 22;388(25):2338-2348 PMID: 37342922 PMCID: PMC10575613 06/21/2023